Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Related Content:

OncLive TVHematologic Oncology
Dr Feldman on the Recognition of Racial Disparities in Breast Cancer
Dr Garrot on Lutetium Lu 177 Vipivotide Tetraxetan in Older Patients with MCRPC
Dr Delforge on the Rationale for CARTITUDE-4 in Lenalidomide-Refractory Myeloma